9 research outputs found
Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis
Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis
NeuroBench: Advancing Neuromorphic Computing through Collaborative, Fair and Representative Benchmarking
The field of neuromorphic computing holds great promise in terms of advancing
computing efficiency and capabilities by following brain-inspired principles.
However, the rich diversity of techniques employed in neuromorphic research has
resulted in a lack of clear standards for benchmarking, hindering effective
evaluation of the advantages and strengths of neuromorphic methods compared to
traditional deep-learning-based methods. This paper presents a collaborative
effort, bringing together members from academia and the industry, to define
benchmarks for neuromorphic computing: NeuroBench. The goals of NeuroBench are
to be a collaborative, fair, and representative benchmark suite developed by
the community, for the community. In this paper, we discuss the challenges
associated with benchmarking neuromorphic solutions, and outline the key
features of NeuroBench. We believe that NeuroBench will be a significant step
towards defining standards that can unify the goals of neuromorphic computing
and drive its technological progress. Please visit neurobench.ai for the latest
updates on the benchmark tasks and metrics
NeuroBench:Advancing Neuromorphic Computing through Collaborative, Fair and Representative Benchmarking
The field of neuromorphic computing holds great promise in terms of advancing computing efficiency and capabilities by following brain-inspired principles. However, the rich diversity of techniques employed in neuromorphic research has resulted in a lack of clear standards for benchmarking, hindering effective evaluation of the advantages and strengths of neuromorphic methods compared to traditional deep-learning-based methods. This paper presents a collaborative effort, bringing together members from academia and the industry, to define benchmarks for neuromorphic computing: NeuroBench. The goals of NeuroBench are to be a collaborative, fair, and representative benchmark suite developed by the community, for the community. In this paper, we discuss the challenges associated with benchmarking neuromorphic solutions, and outline the key features of NeuroBench. We believe that NeuroBench will be a significant step towards defining standards that can unify the goals of neuromorphic computing and drive its technological progress. Please visit neurobench.ai for the latest updates on the benchmark tasks and metrics
Risk factors for Coronavirus disease 2019 (Covid-19) death in a population cohort study from the Western Cape province, South Africa
Risk factors for coronavirus disease 2019 (COVID-19) death in sub-Saharan Africa and the effects of human immunodeficiency virus (HIV) and tuberculosis on COVID-19 outcomes are unknown. We conducted a population cohort study using linked data from adults attending public-sector health facilities in the
Western Cape, South Africa. We used Cox proportional hazards models, adjusted for age, sex, location, and comorbidities, to examine the associations between HIV, tuberculosis, and COVID-19 death from 1 March to 9 June 2020 among (1) public-sector “active patients” (≥1 visit in the 3 years before March 2020); (2) laboratory-diagnosed COVID-19 cases; and (3) hospitalized COVID-19
cases. We calculated the standardized mortality ratio (SMR) for COVID-19, comparing adults living with and without HIV using
modeled population estimates.Among 3 460 932 patients (16% living with HIV), 22 308 were diagnosed with COVID-19, of whom 625 died. COVID19 death was associated with male sex, increasing age, diabetes, hypertension, and chronic kidney disease. HIV was associated with
COVID-19 mortality (adjusted hazard ratio [aHR], 2.14; 95% confidence interval [CI], 1.70–2.70), with similar risks across strata of
viral loads and immunosuppression. Current and previous diagnoses of tuberculosis were associated with COVID-19 death (aHR,
2.70 [95% CI, 1.81–4.04] and 1.51 [95% CI, 1.18–1.93], respectively). The SMR for COVID-19 death associated with HIV was 2.39
(95% CI, 1.96–2.86); population attributable fraction 8.5% (95% CI, 6.1–11.1)